Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Merck
Baxter
Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALBIGLUTIDE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for albiglutide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00518115 Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only Completed GlaxoSmithKline Phase 2 2007-04-01 This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks,and less frequent follow-up visits for an additional 10 weeks. Assessments include repeat blood sampling and monitoring of any side effects.
NCT00838903 Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes Completed GlaxoSmithKline Phase 3 2009-02-01 The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
NCT00838916 A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes Completed GlaxoSmithKline Phase 3 2009-02-01 A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
NCT00839527 A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes Completed GlaxoSmithKline Phase 3 2009-02-01 The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
NCT00849056 Safety and Efficacy of Albiglutide in Type 2 Diabetes Completed GlaxoSmithKline Phase 3 2009-01-01 The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
NCT00976391 A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine Completed GlaxoSmithKline Phase 3 2009-09-01 This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for albiglutide

Condition Name

Condition Name for albiglutide
Intervention Trials
Diabetes Mellitus, Type 2 19
Diabetes Mellitus 2
Type 2 Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for albiglutide
Intervention Trials
Diabetes Mellitus 22
Diabetes Mellitus, Type 2 21
Nausea 1
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for albiglutide

Trials by Country

Trials by Country for albiglutide
Location Trials
United States 397
United Kingdom 30
Germany 30
South Africa 24
Mexico 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for albiglutide
Location Trials
Texas 15
North Carolina 13
Missouri 12
Michigan 12
Kentucky 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for albiglutide

Clinical Trial Phase

Clinical Trial Phase for albiglutide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 14
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for albiglutide
Clinical Trial Phase Trials
Completed 14
Recruiting 4
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for albiglutide

Sponsor Name

Sponsor Name for albiglutide
Sponsor Trials
GlaxoSmithKline 21
PPD 2
The General Hospital Corporation d/b/a Massachusetts General Hospital 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for albiglutide
Sponsor Trials
Industry 24
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Dow
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.